N/A
N=52
Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
Colorectal Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00210106 ↗Enrolled (actual)
52
Serious AEs
10.2%
Results posted
May 2021
Primary outcome: Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ablathermy (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Institut Bergonié
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Hepatic Response Rate at 3 Months |
79 | — |
| SECONDARY Overall Survival |
97.4; 91.7 | — |
| SECONDARY Event-free Survival |
18.4; 10.5 | — |
Summary
The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases. Patients may have benefit or not from a preoperative (neoadjuvant) chemotherapy.
Eligibility Criteria
Inclusion Criteria
Colorectal cancer Hepatic metastases unresectable by classical surgery Performance status < 2
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT00210106). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.